NCT00014729已完成1 期
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
OBJECTIVES:
I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
详细描述
PROTOCOL OUTLINE:
Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
撤回
不适用
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyToxic Epidermal NecrolysisNCT02795143Massachusetts General Hospital
进行中（未招募）
3 期
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsRecessive Dystrophic Epidermolysis BullosaRDEBEpidermolysis BullosaNCT05725018Abeona Therapeutics, Inc12
进行中（未招募）
1 期
Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent GraftsEpidermolysis Bullosa Dystrophica, RecessiveNCT04186650Institut National de la Santé Et de la Recherche Médicale, France3
已完成
4 期
A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and MemoryAcne VulgarisNCT01404130University of Aberdeen18
Unknown
3 期
Isotretinoin in Treatment of COVID-19COVID-19NCT04361422Tanta University300